comparison of Pamidronate and calcium-D effect on bone mineral density of renal transplant patients in Isfahan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138903252417N2

Enrollment

Registered

2010-09-07

Start date

2006-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease. End-stage renal disease

Interventions

Intervention 1: Pamidronate 90mg plus calcium-vitamin D immediately after and after 3 months from renal transplantation. Intervention 2: Calcium-vitamin D (500mg calcium and 400 unit vitamine D).

Treatment - Drugs

Pamidronate 90mg plus calcium-vitamin D immediately after and after 3 months from renal transplantation

Calcium-vitamin D (500mg calcium and 400 unit vitamine D)

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: adult recipients more than 18 years of first or second living donor renal transplant in Isfahan renal transplantation centers. Exclusion criteria: receiving corticosteroid 3 months prior to the renal transplantation (RTx), treating with bisphosphonates, Flouride or Calcitonin any time before RTx, hypercalcemia persisting during the first 2 weeks after RTx, history of previous parathyroidectomy, hemodynamic instability in 24 hours after RTx

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bone mineral density. Timepoint: before and after intervention. Method of measurement: DEXA (dual energy x ray absorptiometry).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Shahrzad Shahidi

Isfahan University of Medical Sciences

shahidi@med.mui.ac.ir+98 31 1663 6858

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026